CTGF/CCN‐2 over‐expression can directly induce features of skeletal muscle dystrophy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Muscular dystrophies are diseases characterized by muscle weakness together with cycles of degeneration and regeneration of muscle fibres, resulting in a progressive decrease of muscle mass, diminished muscle force generation and an increase in fibrosis. Fibrotic disorders are the endpoint of many chronic diseases in different tissues, where accumulation of the extracellular matrix (ECM) occurs. Connective tissue growth factor CTGF/CCN2, which is over‐expressed in muscular dystrophies, plays a major role in many progressive scarring conditions. To test the hypothesis that CTGF might not only contribute conversion of already damaged muscle into scar tissue, but that it could by itself also directly contribute to skeletal muscle deterioration, we evaluated the effect of CTGF over‐expression in tibialis anterior muscle of wild‐type mice, using an adenovirus containing the CTGF mouse sequence (Ad–mCTGF). CTGF over‐expression induced extensive skeletal muscle damage, which was followed by a massive regeneration of the damaged muscle, as evidenced by increased embryonic myosin and fibres with centrally located nuclei. It also induced strong fibrosis with increased levels of fibronectin, collagen, decorin and α‐smooth muscle actin (α‐SMA). Moreover, CTGF over‐expression caused a decrease of the specific isometric contractile force. Strikingly, when CTGF over‐expression stopped, the entire phenotype proved to be reversible, in parallel with normalization of CTGF levels. Thus, CTGF not merely acts downstream of muscle injury but also contributes directly to the deterioration of skeletal muscle phenotype and function. Moreover, normalization of expression levels led to spontaneous reversal of the CTGF‐induced phenotype and to full recovery of muscle structure. These observations underscore the importance of CTGF in the pathophysiology of muscular dystrophies and suggest that targeting CTGF might have significant potential in the development of novel therapies for Duchenne muscular dystrophy and related diseases. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Regulatory interactions between muscle and the immune system during muscle regeneration
Tidball, J. G., & Villalta, S. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00735.2009 · Cited by 1,105 · cited 1×
“These lesions were accompanied by increased numbers of mononuclear cells, probably representing influx of inflammatory cells [24] and proliferation of satellite cells attempting to regenerate the damaged muscle [25].”
BackgroundFunctional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Cited by
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234
“The genes encoding osteopontin (Spp1; 2.1-fold) and connective-tissue growth factor (Ctgf; 1.8-fold), both of which promote skeletal muscle fibrosis and mdx pathology (Morales et al., 2011; Vetrone et al., 2009), were upregulated in the absence of Tregs.”
InfluentialCsapo, R., Gumpenberger, M., & Wessner, B. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00253 · Cited by 429
Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
Skeletal muscle fibrosis: an overview
Mahdy, M. A. A. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-2955-2 · Cited by 363
Abrigo, J., Rivera, J. C., Aravena, J., Cabrera, D., Simon, F., Ezquer, F., Ezquer, M., & Cabello-Verrugio, C. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9047821 · Cited by 109
Self-citationThe Hippo signal transduction network in skeletal and cardiac muscle
Wackerhage, H., Del Re, D. P., Judson, R. N., Sudol, M., & Sadoshima, J. (2014) · Science Signaling · doi:10.1126/scisignal.2005096 · Cited by 92
“Overexpression of Ctgf in mouse skeletal muscle is sufficient to cause muscular dystrophy (162), whereas knockout of Ctgf in a mouse model of muscular dystrophy partially ameliorates the pathology (163).”
BackgroundSkeletal muscle fibrosis in pancreatic Cancer patients with respect to survival
Judge, S. M., Nosacka, R. L., Delitto, D., Gerber, M. H., Cameron, M. E., Trevino, J. G., & Judge, A. R. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky043 · Cited by 91
Cisternas, F., Morales, M. G., Meneses, C., Simon, F., Brandan, E., Abrigo, J., Vazquez, Y., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140215 · Cited by 83
Self-citationAngiotensin-(1-7) attenuates disuse skeletal muscle atrophy via the Mas receptor
Morales, M. G., Abrigo, J., Acuña, M. J., Santos, R. A., Bader, M., Brandan, E., Simon, F., Olguin, H., Cabrera, D., & Cabello-Verrugio, C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.023390 · Cited by 77
Self-citationMorales, M. G., Olguín, H., Di Capua, G., Brandan, E., Simon, F., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140840 · Cited by 62
Self-citationAbrigo, J., Morales, M. G., Simon, F., Cabrera, D., Capua, G. D., & Cabello-Verrugio, C. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.06.011 · Cited by 20
Self-citation
Metadata
- Authors
- Morales, M. G., Cabello‐Verrugio, C., Santander, C., Cabrera, D., Goldschmeding, R., & Brandan, E.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2011-08-08
- Volume
- 225
- Issue
- 4
- Pages
- 490-501
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2078055318
- Cited by
- 107
- References
- 3
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.